Neuromyopathies in the Critically Ill
Neuromuscular disorders are increasingly recognized as a significant contributor of morbidity and mortality in the intensive care unit (ICU). This recognition is largely brought about by the increased awareness of acquired neuromuscular dysfunction following acute life-threatening illness. Indeed, the development of acquired neuromyopathy during the course of treatment of life-threatening illness such as acute myopathy and critical illness polyneuropathy has replaced traditional causes of neuromyopathy (Guillain—Barré syndrome, myasthenia gravis) as the most common origin of muscle weakness in the ICU.
KeywordsForced Vital Capacity Respiratory Muscle Amyotrophic Lateral Sclerosis Patient Neuromuscular Disease Noninvasive Positive Pressure Ventilation
Unable to display preview. Download preview PDF.
- Plasma Exchange/Sandoglobulin Guillain-Barré Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225–230.Google Scholar
- RopperAH. The Guillain-Barre syndrome. N Engl J Med 1992; 326 (6): 1130–1136.Google Scholar